203 related articles for article (PubMed ID: 30916859)
1. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
Ebata R; Yasukawa K; Nagai K; Saito Y; Higashi K; Homma J; Takada N; Takechi F; Saito N; Kobayashi H; Okunushi K; Hamada H; Kohno Y; Hanaoka H; Shimojo N
Pediatr Int; 2019 May; 61(5):438-443. PubMed ID: 30916859
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
3. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
4. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
[TBL] [Abstract][Full Text] [Related]
5. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
Kimura M; Harazaki M; Fukuoka T; Asakura I; Sakai H; Kamimaki T; Ohkawara I; Akiyama N; Tsurui S; Iwashima S; Shimomura M; Morishita H; Meguro T; Seto S
Pediatr Int; 2017 Apr; 59(4):397-403. PubMed ID: 27743415
[TBL] [Abstract][Full Text] [Related]
6. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
Koné-Paut I; Tellier S; Belot A; Brochard K; Guitton C; Marie I; Meinzer U; Cherqaoui B; Galeotti C; Boukhedouni N; Agostini H; Arditi M; Lambert V; Piedvache C
Arthritis Rheumatol; 2021 Jan; 73(1):151-161. PubMed ID: 32779863
[TBL] [Abstract][Full Text] [Related]
7. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.
Suzuki H; Terai M; Hamada H; Honda T; Suenaga T; Takeuchi T; Yoshikawa N; Shibuta S; Miyawaki M; Oishi K; Yamaga H; Aoyagi N; Iwahashi S; Miyashita R; Onouchi Y; Sasago K; Suzuki Y; Hata A
Pediatr Infect Dis J; 2011 Oct; 30(10):871-6. PubMed ID: 21587094
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
[TBL] [Abstract][Full Text] [Related]
10. Ulinastatin therapy in kawasaki disease.
Iwashima S; Seguchi M; Matubayashi T; Ohzeki T
Clin Drug Investig; 2007; 27(10):691-6. PubMed ID: 17803344
[TBL] [Abstract][Full Text] [Related]
11. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
[TBL] [Abstract][Full Text] [Related]
13. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
14. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
16. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
17. High neutrophil : lymphocyte ratio is associated with refractory Kawasaki disease.
Cho HJ; Bak SY; Kim SY; Yoo R; Baek HS; Yang S; Hwang IT; Ban JE
Pediatr Int; 2017 Jun; 59(6):669-674. PubMed ID: 28097746
[TBL] [Abstract][Full Text] [Related]
18. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y; Inuzuka R; Hayashi T; Shindo T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Oka A
Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
[TBL] [Abstract][Full Text] [Related]
19. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
[TBL] [Abstract][Full Text] [Related]
20. Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease.
Kido S; Ae R; Kosami K; Matsubara Y; Makino N; Sasahara T; Kuwabara M; Aoyama Y; Yashiro M; Yanagawa H; Nakamura Y
Pediatr Int; 2019 Jun; 61(6):539-543. PubMed ID: 30980447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
